Ascites: A Potential Diagnostic Surrogate for Genetic Profiling in Ovarian Cancer.

Λεπτομέρειες βιβλιογραφικής εγγραφής
Τίτλος:	Ascites: A Potential Diagnostic Surrogate for Genetic Profiling in Ovarian Cancer.
Συγγραφείς:	Høgdall EV; Molecular Unit, Department of Pathology, Herlev Hospital, University of Copenhagen, Herlev, Denmark; estrid.hoegdall@regionh.dk., Vestergaard LK; Molecular Unit, Department of Pathology, Herlev Hospital, University of Copenhagen, Herlev, Denmark., Oliveira DNP; Molecular Unit, Department of Pathology, Herlev Hospital, University of Copenhagen, Herlev, Denmark., Poulsen TS; Molecular Unit, Department of Pathology, Herlev Hospital, University of Copenhagen, Herlev, Denmark., Høgdall CK; Juliane Marie Centre, Department of Gynecology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
Πηγή:	Anticancer research [Anticancer Res] 2026 May; Vol. 46 (5), pp. 2899-2913.
Τύπος έκδοσης:	Journal Article
Γλώσσα:	English
Στοιχεία περιοδικού:	Publisher: International Institute of Anticancer Research Country of Publication: Greece NLM ID: 8102988 Publication Model: Print Cited Medium: Internet ISSN: 1791-7530 (Electronic) Linking ISSN: 02507005 NLM ISO Abbreviation: Anticancer Res Subsets: MEDLINE
Imprint Name(s):	Publication: Attiki, Greece : International Institute of Anticancer Research Original Publication: Athens, Greece : Potamitis Press
Ιατρικοί όροι (MeSH):	Ovarian Neoplasms/genetics , Ovarian Neoplasms/diagnosis , Ovarian Neoplasms/pathology , Ascites/genetics , Ascites/pathology , Ascites/diagnosis , Biomarkers, Tumor/genetics , Genetic Profile, Humans ; Female ; Aged ; Middle Aged ; High-Throughput Nucleotide Sequencing ; Aged, 80 and over
Περίληψη:	Background/aim: Ovarian cancer is predominantly diagnosed in the late stages of the disease. Ascites can be collected before the start of neoadjuvant treatment or during the treatment course and may serve as a potential biological surrogate for tumor tissue (TT), representing metastases located in the peritoneal cavity. The minimally invasive nature of ascites collection makes it an alternative to tumor biopsies. The aim was to investigate ascites samples alongside corresponding fresh frozen TT to clarify the potential of ascites in reflecting the genetic composition of TT. Secondly, we wanted to investigate if ascites can be used as biological material for molecular analyses, predicting possible molecular targets associated with FDA-approved drugs. Materials and Methods: We used next-generation sequencing, natural language processing, and network analysis to assess the recall of genetic variants between corresponding TT and ascites samples in a cohort of 32 patients with ovarian cancer. Results: Patients median age was 68.5 years. Seventy two percent were diagnosed at late stage disease. Overall, the analysis showed that 156 (76%) of the identified variants overlapped between ascites and TT. Ascites had 28 (14%) unique identified variants, while TT had 21 (10%). We identified 25 (76%) pathogenic or likely pathogenic variants in TT that were also present in the corresponding ascites sample. Three variants (9%) were unique for the ascites samples, while five (15%) were unique for the TT samples. Conclusion: We identified all pathogenic and likely pathogenic actionable variants within a clinical perspective in ascites. Clinicians may consider using ascites, particularly for patients with fluid accumulation who are not candidates for surgery at the time of diagnosis. (Copyright © 2026 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.)
Contributed Indexing:	Keywords: Ovarian cancer; ascites; bioinformatics; ctDNA; natural language processing; next-generation sequencing; targeted therapeutics
Substance Nomenclature:	0 (Biomarkers, Tumor)
Entry Date(s):	Date Created: 20260428 Date Completed: 20260715 Latest Revision: 20260715
Update Code:	20260716
DOI:	10.21873/anticanres.18168
PMID:	42049358
Βάση Δεδομένων:	MEDLINE

Περιγραφή
ISSN:	1791-7530
DOI:	10.21873/anticanres.18168